即时检验与居家检测:粪便检测、血清检测及肠道超声广泛整合的务实考量
在炎症性肠病治疗疗效平台期的背景下,紧控模式需个体化生物标志物。本文综述即时检验与居家检测的现状、务实考量及未来意义,包括由治疗消化科医生操作的即时肠道超声、血清与粪便生物标志物及电子健康监测的联合应用。
要点
- 紧控模式需早期风险分层后序贯监测以快速调整治疗。
- 即时肠道超声由治疗消化科医生操作,可实时监测肠道炎症。
- 肠道超声联合血清、粪便生物标志物及居家电子监测可能优化个体化治疗。
核心结论
- 即时肠道超声联合血清和粪便生物标志物及居家电子健康监测可形成以患者为中心的个体化治疗算法,可能改善治疗结局。
研究设计与样本
- 综述,总结即时检验与居家检测用于炎症性肠病无创监测的现状、务实考量与未来意义。
主要发现
- 突破生物制剂疗效平台期需在紧控模式下战略开发个体化生物标志物。
- 早期风险分层后靶向序贯监测评估临床结局,可在肠损伤发生前快速调整治疗。
- 由治疗消化科医生操作的即时肠道超声是准确的横断面生物标志物,可实时监测肠道炎症、提升患者照护并增进共同理解以达共同治疗目标。
临床怎么用
- 作者认为,将门诊肠道超声与现有血清和粪便生物标志物及居家电子健康监测结合,可形成优化的以患者为中心的个体化治疗算法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monitoring consistently to assess clinical outcomes in response to therapy allows for quick therapeutic adjustments before bowel damage can occur. Point-of-care intestinal ultrasound performed by the treating gastroenterologist is an accurate cross- sectional biomarker that monitors intestinal inflammation in real-time, enhances patient care, and increases shared understanding to help achieve common treatment goals. Combining intestinal ultrasound during a clinic visit with existing serum and stool biomarkers in a home testing setup with electronic health monitoring allows for an optimized, patient-centered personalized treatment algorithm that may improve treatment outcomes. Here, we review the current state, pragmatic considerations, and future implications of point-of-care testing and home testing for noninvasive inflammatory bowel disease monitoring in the tight control model.
引用
- Wilkens R, Dolinger M, Burisch J, et al. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology. 2022. PMID: 34995530. doi:10.1053/j.gastro.2021.10.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。